Comparison of Prasugrel and Clopidogrel in Thrombotic Stroke Patients with Risk Factors for Ischemic Stroke Recurrence: An Integrated Analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III
Conclusions: This integrated analysis supports the findings of PRASTRO-III. Prasugrel is a promising treatment that results in a numerical reduction in the composite incidence of ischemic stroke, MI, and death from other vascular causes in patients with ischemic stroke who are at a high risk of stroke recurrence. No major safety issues were observed for prasugrel.Cerebrovasc Dis
Source: Cerebrovascular Diseases - Category: Neurology Source Type: research
More News: Bleeding | Cardiology | Chronic Kidney Disease | Clopidogrel | Diabetes | Diabetes Mellitus | Endocrinology | Heart | Heart Attack | Hypertension | Ischemic Stroke | Neurology | Plavix | Stroke | Study | Urology & Nephrology